Recent advances on development of p21-activated kinase 4 inhibitors as anti-tumor agents
The p21-activated kinase 4 (PAK4) is part of the PAKs family. It’s overexpressed in multiple tumor tissues. Medicinal inhibition of PAK4 attenuates proliferation, migration, and invasion of cancer cells. Recent reports says inhibition of PAK4 sensitizes immunotherapy that has been extensively exploited like a new technique to treat cancer. Previously couple of years, a lot of PAK4 inhibitors happen to be reported. Of note, the allosteric inhibitor KPT-9274 continues to be tested in phase ? clinic trials. Herein, we offer an update on recent research progress around the PAK4 mediated KPT 9274 signaling path and highlight the introduction of the PAK4 small molecular inhibitors in recent five years. Meanwhile, challenges, limitations, and future developmental directions is going to be discussed too.